黑料网

Archives of Science
黑料网

Our Group organises 3000+ Global Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ 黑料网 Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

黑料网 Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Mini Review   
  • Arch Sci 2023, Vol 7(3): 154
  • DOI: 10.4172/science.1000154

Therapeutically Growth in Oligodendroglia Fate Induction via Trans Differentiation of Stem Cells for Neurodegenerative Therapy

Darcy Armour*
Department of Microbiology, College of Medicine, Ethiopia
*Corresponding Author: Darcy Armour, Department of Microbiology, College of Medicine, Ethiopia, Email: Darcy23@gmail.com

Received: 01-May-2023 / Manuscript No. science-23-91436 / Editor assigned: 03-May-2023 / PreQC No. science-23-91436 / Reviewed: 17-May-2023 / QC No. science-23-91436 / Revised: 23-May-2023 / Manuscript No. science-23-91436 / Published Date: 29-May-2023 DOI: 10.4172/science.1000154

Abstract

The benefits of stem cell therapy and research are undeniable given how frequently they are used to treat demyelinating illnesses and neurodegenerative diseases. Prior to transplantation or disease modelling research, stem cells are induced into several cell lineages, both adult and progenitor - belonging to each germ layer - in cell replacement treatment. The nervous system contains a large number of glial cells, including oligodendrocytes, which can remyelinate axons that have lost or damaged myelin sheaths as well as myelinate newly formed neurons. Yet, myelin breakdown and regeneration are drastically outpaced by demyelinating illnesses. Mesenchymal stem cells (MSCs) have been stimulated to transdifferentiate in order to make up for this loss, examine the abnormalities in remyelination pathways, and accelerate full recovery in such individuals.

Keywords

Oligodendroglial fate induction; Stem cells; Neuroregenerative therapy

Introduction

Neurodegenerative illnesses frequently include progressive and untimely neuronal cell loss. In general, neurodegenerative illnesses are an outcome of a broad spectrum of factors like age, heredity, and environment, and the causation of each varies correspondingly [1]. The processes that cause neuronal degeneration are currently being investigated. The prevention and treatment of neurological illnesses must be improved immediately [2]. As they preserve the neurons in a functional state, the supporting cells of the nervous system known as glial cells are as important to a portion of neurodegenerative illnesses as the neurons themselves. The nervous system’s homeostatic and protective neuroglia is comprised of very varied cellular populations with varying ancestry, structure, and function.

Mesenchymal stem cells

Glial cells called oligodendrocytes create myelin, the coating that covers axons and is rich in lipids. In the central nervous system (CNS), the myelin sheath is necessary for the salutatory conduction of action potentials. Any harm to the oligodendrocytes or the myelin sheath has a serious impact on how well neurons function. Demyelination of axons is an essential element causing function loss in many neurological conditions (multiple sclerosis, stroke, spinal cord injury (SCI), trauma, leukodystrophies, etc.). Unexpectedly, recent research on the deterioration and death of motor neurons found that oligodendrocytes (OLs) play an early involvement in the onset of multiple sclerosis (MS). The causes of MS-related neurodegeneration caused by the autoinflammatory response are unclear. Another significant disadvantage is the lack of medicines that can take advantage of people with high risk levels who are genetically predisposed to MS. Similar to progressive MS, oligodendrocyte progenitor cell (OPC) maturation abnormalities and OL degeneration in ALS lead to myelin degradation and eventual neuronal death [3,4]. It has been suggested that ALS-causing genes that interfere with the efficiency of myelin-related mRNA processing are the ones that cause OL disintegration in ALS patients. Moreover, these genes produce protein mutants that agglomerate and become toxic. Routes that directly control OL differentiation are negatively impacted, which could result in OPCs failing to mature as is the case with ALS. In ALS, the normal metabolic and trophic support provided by OLs to neurons is down-regulated, which significantly impairs axon shape and function [5, 6]. All neuronal degeneration cases include intricate mechanisms with numerous cascading pathways. In laboratory models, researchers have had some success targeting one molecule at a time and blocking one route at a time. There hasn’t yet been any human success using these techniques. The specific cause of neuronal cell death and the aetiology of the majority of these disorders are unknown at this time. Even though the pathogenic processes are poorly understood, earlier research indicates that significant function recovery may be possible by demyelination of undamaged axons. Functional recovery by demyelination may show to be a practical replacement and regeneration strategy when used as a treatment technique [7].

A desirable cell source for cell therapy and regeneration is stem cell therapy. The potential use of neuronal replacement therapy has significantly improved because to the use of stem cells and strictly regulated cellular programming techniques. The length of the motor axons and the mounting evidence that the neurodegeneration in ALS may be mediated by neuronal and glial effects make stem cell therapy more difficult in ALS than in other neurodegenerative illnesses. Recent research demonstrated that stem cells can multiply, migrate, and develop into neurons and glial cells within injured brain and spinal cord tissue [8].

Conclusion

Without the efforts, mistakes, and corrections made with ESCs and iPSCs, the current procedures for oligodendroglia lineage commitment would not exist. 3-D cultures have emerged as an innovative example of differentiation induction techniques that can imitate in vivo conditions [9, 10].

Acknowledgement

None.

Conflict of Interest

None.

References

  1. Sharma B, Malik P, Jain P (2018) Biopolymer reinforced nanocomposites: A comprehensive review Mater. Today Commun 16:353-363.
  2. Crossref

  3. Titone V, Correnti A, La Mantia FP (2021) Effect of moisture content on a biodegradable polyester’s processing and mechanical properties. Polymers13:1616.
  4. Indexed at, Crossref

  5. Ates B, Koytepe S, Ulu A, Gurses C, Thakur VK (2020) Chemistry, structures, and advanced applications of nanocomposites from biorenewable resources. Chem Rev120: 9304-9362.
  6. Indexed at, Crossref

  7. Remiš T, Belský P, Kovárík T, Kadlec J, Azar MG (2021) Study on structure, thermal behavior, and viscoelastic properties of nanodiamond-reinforced poly (vinyl alcohol) nanocomposites. Polymers 13:1426.
  8. Indexed at, Crossref

  9. Rouf TB, Kokini JL (2016) Biodegradable biopolymer–graphene nanocomposites. J Mater Sci 51:9915-9945.
  10. Crossref

  11. Fukushima K, Abbate C, Tabuani D, Gennari M, Camino G (2009) Biodegradation of poly(lactic acid) and its nanocomposites. Polym Degrad Stab 94:1646-1655.
  12. Crossref

  13. Murariu M, Dubois P (2016) PLA composites: From production to properties. Adv Drug Deliv Rev107:17-46.
  14. Indexed at, Crossref

  15. Pandey JK, Reddy KR, Pratheep Kumar A, Singh RP (2005) An overview on the degradability of polymer nanocomposites. Polym Degrad Stab 88:234-250.
  16. Crossref

  17. Chang BP, Mohanty AK, Misra M (2020) Studies on durability of sustainable biobased composites: A review. RSC Adv10:17955.
  18. Crossref

  19. Li M, Li D, Wang LJ, Adhikari B (2015) Creep behavior of starch-based nanocomposite films with cellulose nanofibrils. Carbohydr Polym 117:957-963.
  20. Indexed at, Crossref

Citation: Armour D (2023) Therapeutically Growth in Oligodendroglia FateInduction via Trans Differentiation of Stem Cells for Neurodegenerative Therapy.Arch Sci 7: 154. DOI: 10.4172/science.1000154

Copyright: © 2023 Armour D. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.

International Conferences 2024-25
 
Meet Inspiring Speakers and Experts at our 3000+ Global

Conferences by Country

Medical & Clinical Conferences

Conferences By Subject

Top